Challenges Facing Prostate Cancer Equity
Brandon Mahal, MD, discusses challenges facing prostate cancer equity.
Brandon Mahal, MD, an assistant professor at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, discusses challenges facing prostate cancer equity.
According to Mahal, there are only 3 well-established prostate cancer risk factors: age, family history, and race. Mahal notes that while race is a social construct, the factors driving race such as culture and environmental influences are very real. They inform race, which creates the social structure.
In order to better understand prostate cancer risk factors, we must better understand race, according to Mahal. It shouldn’t be that race is the underlying driving factor, but what is driving race, such as the environment and structural racism. According to Mahal, physicians must themselves to understand the factors driving race. By doing so, the field will have better knowledge around what drives prostate cancer risk.
First Real-World Data on Second-Generation AR Inhibitor Use in nmCRPC
September 18th 2023A review of real-world data from the DEAR study of darolutamide, enzalutamide and apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer is given by Alicia Morgans, MD, MPH.
Listen
BXCL701 Gains Fast Track Designation for mCRPC Treatment
February 13th 2024The FDA has granted fast track designation to BXCL701 with an immune checkpoint inhibitor for metastatic small cell neuroendocrine prostate cancer resistant to chemotherapy and showing no evidence of microsatellite instability.
Read More
